88 stocks traded in large quantities! Hengrui Pharmaceutical and other three pharmaceutical companies ranked first in terms of turnover

According to relevant statistics, on January 11, a total of 88 stocks in the two cities had large transactions, with a total transaction volume of 3.
53 billion yuan, of which Hengrui Pharmaceutical's turnover was 862 million yuan, WuXi AppTec was 597 million yuan, and Kailaiying was 371 million yuan, and these three companies had the highest turnover
.
According to statistics, on January 11, Hengrui Pharmaceutical's block trade traded 23.
4675 million shares, with a turnover of 862 million yuan, accounting for 29.
4% of the total transaction volume on the day, and the transaction price was 36.
72 yuan, a discount of 4.
5%
compared with the market closing price of 38.
45 yuan.
It is understood that Hengrui Pharmaceutical, as an innovative international pharmaceutical enterprise, has steadily promoted the two-wheel drive development strategy
of innovation and internationalization in recent years.
The company has successively set up R&D centers or branches in Lianyungang, Shanghai, Chengdu, the United States and Europe, and has built a large-scale, professional and comprehensive global R&D team
of more than 5,000 people.
At present, Hengrui Pharmaceutical has 11 innovative drugs such as reverutamide, dalcilide and carrelizumab approved for marketing, and the first class new drug introduced by the company, Linplisac, has also been approved for marketing recently, and more than 60 innovative drugs are under clinical development, and more than 260 clinical trials are carried out
at home and abroad.
At the same time, relying on the global innovation system, Hengrui Pharmaceutical has steadily promoted the international progress of innovative drugs, and has carried out nearly 20 international clinical trials, and actively promoted the overseas licensing of innovative drugs with independent intellectual property rights, and strived to promote innovation "going overseas"
.
Data show that on January 11, WuXi AppTec traded 7.
0605 million shares in block trading, with a turnover of 597 million yuan, accounting for 25.
24% of the total turnover on the day, and the transaction price was 84.
6 yuan, a discount of 5.
54%
from the market closing price of 89.
56 yuan.
According to the data, WuXi AppTec provides integrated, end-to-end new drug development and manufacturing services
for the global biomedical industry.
Through its "CRDMO" and "CTDMO" business models, WuXi AppTec continues to lower the threshold for R&D, help customers improve R&D efficiency, and bring more breakthrough treatment options to patients, covering chemical drug R&D and manufacturing, biological research, preclinical testing and clinical trial R&D, cell and gene therapy R&D, testing and manufacturing
。 Some industry insiders said that WuXi AppTec's new business such as peptide and oligonucleotide CDMO and formulation CDMO global layout is expected to drive the small molecule CDMO business to achieve a higher compound revenue growth
rate that exceeds the industry in the 2023-2025 or even longer time horizon.
Data show that on January 11, a total of 36 transactions occurred on the Kailaiying block trading platform, with a total volume of 2.
6049 million shares and a transaction amount of 371 million yuan
.
According to further statistics, a total of 50 large transactions have occurred in the stock in the past three months, with a total transaction amount of 577 million yuan
.
Over the years, Kaileying has served many pharmaceutical companies at home and abroad in the field of antiviral, anti-infection, anti-tumor, cardiovascular, nervous system, diabetes and other major disease treatment of innovative drug products
.
It is understood that Kaileying has always been known for its small molecule CDMO business
.
According to statistics, in terms of revenue in 2020, Kaileying is a large-scale commercial-stage chemical drug CDMO company
in China.
Moreover, in the existing business of Gloria Ying, more revenue and orders also come from small molecule CDMO
.
Financial information shows that in the first half of 2022, Kaileying achieved revenue of 5.
041 billion yuan, a year-on-year increase of 186.
4%.

Among them, CDMO in the clinical stage achieved revenue of 968 million yuan, a year-on-year increase of 16.
73%; In the commercialization stage, CDMO achieved revenue of 3.
676 billion yuan, a year-on-year increase of 366.
79%.

The sum of these two parts of revenue has accounted for more than
ninety percent of the company's revenue in the same period.
However, Kaileying once said in an institutional survey that the company's emerging business segment is in a period of rapid business expansion, and large-scale production capacity will be launched in the next two years, of which the chemical macromolecule project is expected to complete the construction of about 12,000m² of R&D center and about 9,500m² of GMP (Good Manufacturing Practice) production plant by the end of 2022; In terms of biological macromolecules, Shanghai and Suzhou have continued to invest.

Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.